Our aim is to assess the long-term health effects and cost-effectiveness of PSA screening with S3M used as a reflex test above a PSA of 1, 1.5 or 2 ng/mL compared with no prostate cancer screening or PSA screening alone. This evidence concerns the gene KLK3 and prostate carcinoma.